EGFR TKI (3rd generation) · small molecule
rociletinib
0 active trials across 2 of our biomarkers, targeting EGFR. Not approved for any biomarker on marked.bio yet.
Also known as CO-1686.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 0 | 7 | – |
| EGFR exon 20 insertion | 0 | 1 | – |
Trials
0 of 7 trials shown
-
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
rociletinibpemetrexedgemcitabinepaclitaxeldocetaxel
Documented evidence of a tumor with 1 or more EGFR activating mutations excluding exon 20 insertion
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
rociletiniberlotinib FDA EU
Documented evidence of a tumor with activating EGFR mutations by local testing.
EGFR exon 19 deletion / L858REGFR exon 20 insertionNon-Small Cell Lung Cancer
-
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
…cally advanced or metastatic NSCLC, with one or more activating EGFR mutation (eg, G719X, exon 19 deletion, L858R, L861Q) and absence of exon 20 insertion
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
…B/IV lung adenocarcinoma with known activating mutations in the EGFR TK domain (including exon 19 deletion and L858R)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
-
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
…gically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion)
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
Documented evidence of a tumor with 1 or more EGFR mutations excluding exon 20 insertion
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Evidence of a tumor with one or more EGFR mutations excluding exon 20 insertion
EGFR exon 19 deletion / L858RLocally Advanced or Metastatic Non Small Cell Lung Cancer
No trials match these filters.